secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001493152-23-038736
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma licenses predictive biomarker IP from Georgetown for prostate cancer RT
--------------------------------------------------------------------------------

- Exclusive license for patent application 17/476,184 ("Predictive Biomarkers for Adverse Effects of Radiation Therapy") from Georgetown University.
- Upfront payment, maintenance fees, and milestone payments tied to validation trial, FDA approval, and commercial sales; 5% earned royalty on net sales.
- IP developed by CEO Dr. Anatoly Dritschilo, Principal Scientist Dr. Scott Grindrod, and Georgetown researchers.
- Company completed Phase I/II NIH SBIR contracts for the biomarker program; plans to seek Phase IIb SBIR bridge funding.
- Program targets a blood test to predict radiation therapy outcomes for ~66,000 prostate cancer patients annually in the US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/0001493152-23-038736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer